Free Trial
NASDAQ:CMMB

Chemomab Therapeutics (CMMB) Stock Price, News & Analysis

Chemomab Therapeutics logo
$3.48 +0.08 (+2.35%)
Closing price 04:00 PM Eastern
Extended Trading
$3.50 +0.02 (+0.57%)
As of 06:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Chemomab Therapeutics Stock (NASDAQ:CMMB)

Key Stats

Today's Range
$3.35
$3.78
50-Day Range
$0.87
$3.40
52-Week Range
$3.32
$10.20
Volume
710,375 shs
Average Volume
60,946 shs
Market Capitalization
$65.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$26.50
Consensus Rating
Buy

Company Overview

Chemomab Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
65th Percentile Overall Score

CMMB MarketRank™: 

Chemomab Therapeutics scored higher than 65% of companies evaluated by MarketBeat, and ranked 358th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Chemomab Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Chemomab Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Chemomab Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Chemomab Therapeutics are expected to grow in the coming year, from ($1.00) to ($0.70) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Chemomab Therapeutics is -5.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Chemomab Therapeutics is -5.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Chemomab Therapeutics has a P/B Ratio of 6.82. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Chemomab Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    0.72% of the float of Chemomab Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Chemomab Therapeutics has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Chemomab Therapeutics has recently decreased by 30.01%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Chemomab Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Chemomab Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.72% of the float of Chemomab Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Chemomab Therapeutics has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Chemomab Therapeutics has recently decreased by 30.01%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Chemomab Therapeutics has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.97 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 11 news articles for Chemomab Therapeutics this week, compared to 1 article on an average week.
  • MarketBeat Follows

    2 people have added Chemomab Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Chemomab Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    11.91% of the stock of Chemomab Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    46.05% of the stock of Chemomab Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Chemomab Therapeutics' insider trading history.
Receive CMMB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chemomab Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CMMB Stock News Headlines

Q3 EPS Forecast for Chemomab Therapeutics Raised by Analyst
The Coin That Could Define Trump’s Crypto Presidency
When Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top advisor on crypto and AI. That alone signaled a shift. But insiders close to D.C. aren’t just talking crypto policy—they’re quietly buying something most retail investors have missed. While the crowd chases Bitcoin to $150,000, Weiss Ratings expert Juan Villaverde believes a different coin—already backed by giants like Google, Visa, and PayPal—could soon become crypto’s “Third Giant.”tc pixel
See More Headlines

CMMB Stock Analysis - Frequently Asked Questions

Chemomab Therapeutics' stock was trading at $7.24 at the start of the year. Since then, CMMB stock has decreased by 51.9% and is now trading at $3.48.

Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) released its earnings results on Thursday, August, 14th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.80) by $0.44.

Chemomab Therapeutics's stock reverse split on the morning of Tuesday, August 26th 2025.A 1-4 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 25th 2025. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

Chemomab Therapeutics' top institutional shareholders include Orbimed Advisors LLC (4.99%). Insiders that own company stock include Israel Gp Ltd Orbimed, George Adi Mor and Neil Harris Cohen.
View institutional ownership trends
.

Shares of CMMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Chemomab Therapeutics investors own include Arista Networks (ANET), Broadcom (AVGO), CrowdStrike (CRWD), ServiceNow (NOW), NVIDIA (NVDA), Meta Platforms (META) and Adobe (ADBE).

Company Calendar

Last Earnings
8/14/2025
Today
8/27/2025
Next Earnings (Estimated)
11/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CMMB
CIK
1534248
Fax
N/A
Employees
20
Year Founded
N/A

Price Target and Rating

High Price Target
$28.00
Low Price Target
$25.00
Potential Upside/Downside
+617.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.59)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$13.94 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-94.71%
Return on Assets
-76.53%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.42
Quick Ratio
7.42

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.51 per share
Price / Book
7.24

Miscellaneous

Outstanding Shares
18,860,000
Free Float
16,611,000
Market Cap
$69.63 million
Optionable
Not Optionable
Beta
0.52
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NASDAQ:CMMB) was last updated on 8/27/2025 by MarketBeat.com Staff
From Our Partners